Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case–control study, Spain, 2023/24 season
Background Respiratory syncytial virus (RSV) causes substantial morbidity in infants < 1 year. In October 2023, Spain recommended the monoclonal antibody nirsevimab to all children born since 1 April 2023, at birth or as catch-up if born before October 2023. Aim We estimated nirsevimab effectiveness...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
European Centre for Disease Prevention and Control
2025-02-01
|
| シリーズ: | Eurosurveillance |
| 主題: | |
| オンライン･アクセス: | https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2025.30.5.2400596 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|